Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV

Abroad (travel likely)RecruitingPHASE2

Conditions

Polycythemia Vera

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Institute of Hematology & Blood Diseases Hospital, Tianjin, China
Contact: Study coordinator (Lei Zhang, MD) · zhanglei1@ihcams.ac.cn · 8602223909240

Study leads

Lei Zhang, MD
Principal Investigator
Institute of Hematology & Blood Diseases Hospital, China
Rongfeng Fu
Principal Investigator
Institute of Hematology & Blood Diseases Hospital, China

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF)

Primary Myelofibrosis · Post-polycythemia Vera Myelofibrosis · Post-Essential Thrombocytosis Myelofibrosis

Abroad (travel likely)RecruitingPHASE1, PHASE2

Houston, United States

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Acute Myeloid Leukemia · Essential Thrombocythemia · Myelodysplastic Syndrome

Abroad (travel likely)RecruitingPHASE2

Seattle, United States

Ruxolitinib in Thrombocythemia and Polycythemia Vera

Essential Thrombocythemia · Polycythemia Vera

Abroad (travel likely)RecruitingPHASE2

Boston, United States · Boston, United States

Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis

Primary Myelofibrosis (PMF) · Post-polycythemia Vera Myelofibrosis (Post-PV MF) · Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Abroad (travel likely)RecruitingPHASE1

Kamogawa, Japan · Sapporo, Japan